Volume 2, Issue 6 , Pages 462-468, November 2008
Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension
To access this article, please choose from the options below
This article was supported by Pfizer, Inc (IIR no. 2004-0619) and by an unrestricted, investigator-initiated research Grant from University of Connecticut Health Center Clinical Trials Unit, Farmington, Connecticut.
Dr. Calhoun has served as a consultant to Novartis and is a member of the Pfizer speaker's bureau. Dr. White has served as a consultant to Pfizer on the topic of cardiovascular effects of arthritis therapies.
PII: S1933-1711(08)00093-4
doi:10.1016/j.jash.2008.05.005
© 2008 American Society of Hypertension. Published by Elsevier Inc. All rights reserved.
Volume 2, Issue 6 , Pages 462-468, November 2008
